A NORTH-EAST organisation that helps to develop the next generation of products and processes is supporting a new healthcare collaboration.
The Centre for Process Innovation (CPI) is working alongside Cobra Biologics and GE Healthcare Life Sciences on a project to support the development of cost-effective regenerative medicines.
Gene therapy involves the delivery of therapeutic DNA into patients’ cells to correct genetic disorders, make therapeutic proteins, and help immune systems better fight cancer.
The research has been developing rapidly and while only a small number of treatments are already approved for use, more than 200 clinical trials are underway.
Dr John Liddell, CPI senior scientific advisor, said: “CPI is delighted to be working with GE Healthcare Life Sciences and Cobra Biologics on this exciting project working to help develop robust and efficient downstream processes for the rapidly developing area of gene therapy.
“Gene therapies have the potential to be transformative for areas of unmet clinical need and effective manufacturing processes which are the subject of this project, will be important enablers to achieving commercialisation."
Comments: Our rules
We want our comments to be a lively and valuable part of our community - a place where readers can debate and engage with the most important local issues. The ability to comment on our stories is a privilege, not a right, however, and that privilege may be withdrawn if it is abused or misused.
Please report any comments that break our rules.
Read the rules here